- Home
- RARE vs SYBT Comparison
RARE vs SYBT Comparison
Compare RARE & SYBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | SYBT |
|---|---|---|
| Founded | 2010 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2013 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RARE | SYBT |
|---|---|---|
| Price | $30.77 | $76.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 4 |
| Target Price | $59.10 | ★ $76.00 |
| AVG Volume (30 Days) | ★ 1.8M | 167.3K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.81% |
| EPS Growth | 7.31 | ★ 22.11 |
| EPS | N/A | ★ 1.24 |
| Revenue | ★ $673,000,000.00 | $23,406,000.00 |
| Revenue This Year | $13.12 | $17.31 |
| Revenue Next Year | $37.80 | $9.32 |
| P/E Ratio | ★ N/A | $61.17 |
| Revenue Growth | ★ 20.13 | 3.37 |
| 52 Week Low | $18.29 | $61.51 |
| 52 Week High | $39.98 | $83.83 |
Technical Indicators
Market Signals| Indicator | RARE | SYBT |
|---|---|---|
| Relative Strength Index (RSI) | 73.20 | 62.64 |
| Support Level | $29.57 | $68.40 |
| Resistance Level | $34.01 | N/A |
| Average True Range (ATR) | 1.26 | 1.93 |
| MACD | 0.65 | 0.19 |
| Stochastic Oscillator | 90.71 | 76.42 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.